Treatment of Tendon Disease Using Autologous Adipose-derived Mesenchymal Stem Cells
Rotator Cuff Tear, Lateral Epicondylitis
About this trial
This is an interventional treatment trial for Rotator Cuff Tear focused on measuring Adipose-drived mesenchymal stem cells, Rotator cuff injury, Lateral Epicondylitis, Randomized controlled trials
Eligibility Criteria
Inclusion Criteria:
- clinically diagnosed as rotator cuff tear or lateral epicondylitis (tennis elbow);
- symptom duration is over 3 months, non-steroidal drug treatment , rehabilitation treatment and other conservative treatment is invalid;
- patient that can understand the clinical trials and signed the informed consent.
Exclusion Criteria:
- patient that underwent other injection treatment within 6 weeks
- some associated diseases (such as arthritis, synovitis, entrapment of related nerve, radiculopathy to the target lesion, generalized pain syndrome, rheumatoid arthritis, pregnancy, impaired sensibility, paralysis, history of allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue)
- patient that enrolled other clinical trials within 3 months
- history of drug/alcohol addiction, habitual smoker
Sites / Locations
- Weiliang Shen
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Autologous adipose-derived MSCs
Compound betamethasone
The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.